Breast cancer is the leading cause of death among American women who are 35 to 55 years of age. We have cloned a novel human homeobox gene called BP1 which is a potential target for therapy of breast cancer. In tumors from 15 patients with newly diagnosed breast cancer, we found that 13 of the 15 (87%) expressed high levels of BP1 mRNA, whereas BP1 mRNA was undetectable in the remaining 13%. In contrast, BP1 was expressed (at a very low level) in only one of six normal breast tissues. BP1 expression was seen in 100% of the high grade, estrogen receptor (ER) negative, progesterone receptor (PR) negative cancers, but in only 33% of ER positive, PR positive breast cancers. Interestingly, BP1 mRNA levels were also found to be high in breast cancer cell lines which are known to be tumorigenic. In this application, we will test the hypothesis that BP1 is a new therapeutic target in breast cancer by analyzing additional tumors and using molecular techniques. Currently we are measuring BP1 in breast tumors by RT-PCR. In this application, immunohistochemical analysis will be developed to facilitate analysis of BP1 expression in histological sections. Of relevance to this grant, previous molecular studies in leukemia suggest that BP1 expression is transforming and is required for survival of a leukemia cell line. If BP1 is part of an anti-apoptotic pathway, its expression may be important in breast cancer cells as well. Stable breast cancer cell lines overexpressing BP1 will be established to determine whether BP1 expression is transforming in vitro. Analysis of a gene array using these cell lines will help to identify genes which may be targets of BP1 and pathways in which it is involved. To determine whether decreasing BP1 levels leads to growth inhibition or apoptosis, BP1 expression will be reduced in breast cancer cell lines using genetic and pharmacological methods. This study will therefore combine clinical and genetic approaches to determine the importance of BP1 expression in breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA091149-02
Application #
6623512
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Arya, Suresh
Project Start
2002-04-01
Project End
2005-03-31
Budget Start
2003-04-01
Budget End
2005-03-31
Support Year
2
Fiscal Year
2003
Total Cost
$266,000
Indirect Cost
Name
George Washington University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
043990498
City
Washington
State
DC
Country
United States
Zip Code
20052
Stevenson, Holly S; Fu, Sidney W; Pinzone, Joseph J et al. (2007) BP1 transcriptionally activates bcl-2 and inhibits TNFalpha-induced cell death in MCF7 breast cancer cells. Breast Cancer Res 9:R60
Man, Yan-gao; Fu, Sidney W; Schwartz, Arnold et al. (2005) Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat 90:241-7
Man, Yan-Gao; Shen, Ting; Weisz, Judith et al. (2005) A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev 29:323-31
Pinzone, Joseph J; Stevenson, Holly; Strobl, Jeannine S et al. (2004) Molecular and cellular determinants of estrogen receptor alpha expression. Mol Cell Biol 24:4605-12
Fu, Sidney W; Schwartz, Arnold; Stevenson, Holly et al. (2003) Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer. Breast Cancer Res 5:R82-7